PRODUCTION AND TESTING OF A MODIFIED VACCINIA ANKARA (MVA) VACCINE
$6,072,797N01FY2014AINIH
Sanofi Pasteur Biologics, Llc, Cambridge MA
Investigators
Abstract
The purpose of this contract is to support the advanced development and manufacture of a Modified Vaccinia Ankara (MVA) smallpox vaccine.
View original record on NIH RePORTER →